Fig. 1
BRK is overexpressed in most human tumors. a Differential expression data of BRK mRNA between normal and tumor tissue for 24 human cancers. Data obtained from The Cancer Genome Atlas database, median ± one quartile; *p < 0.05; **p < 0.01; ***p < 0.001; ns = not significant (also see Additional file 1: Table S1 for details). Tissue samples are denoted N for normal and T for tumor. BLCA = bladder urothelial carcinoma, BRCA = breast carcinoma, CESC = cervical squamous cell carcinoma, CHOL = cholangiocarcinoma, COAD = colon adenocarcinoma1, ESCA = esophageal cancer, GBM = glioblastoma multiforme, HNSC = head and neck squamous cell carcinoma, KICH = chromophobe renal cell carcinoma, KIRC = clear cell kidney carcinoma, KIRP = papillary kidney carcinoma, LIHC = liver hepatocellular carcinoma, LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, PAAD = pancreatic ductal carcinoma, PCPG = pheochromocytoma and paraganglioma, PRAD = prostate adenocarcinoma, READ = rectal adenocarcinoma, SARC = sarcoma, SKCM = cutaneous melanoma, STAD = stomach adenocarcinoma, THCA = papillary thyroid carcinoma, THYM = thymoma, UCEC = uterine corpus endometrial carcinoma. b BRK transcript levels are significantly higher in ER-positive breast cancers. Data on BRK gene expression mined from The Cancer Genome Atlas (TCGA) database. Analyses of TCGA data were performed on breast tissue samples with RNA-sequencing data. Log2 transformed data was obtained from normal mammary tissue samples (n = 114) and from a total of 683 breast cancers classified as ER-positive (n = 492), HER2-postive (n = 39), and TNBC (n = 152). Statistical significance was calculated against the normal tissue: p-value 8.1 × 10− 45 (ER-positive); p-value 2.3 × 10− 11 (HER2-postive); p-value 0.002 (TNBC). P < 0.005 = significant